Dissemin is shutting down on January 1st, 2025

Published in

MDPI, International Journal of Environmental Research and Public Health, 12(18), p. 6384, 2021

DOI: 10.3390/ijerph18126384

Links

Tools

Export citation

Search in Google Scholar

Effect of PM2.5 Levels on Respiratory Pediatric ED Visits in a Semi-Urban Greek Peninsula

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Ambient air pollution accounts for an estimated 4.2 million deaths worldwide. Particulate matter (PM)2.5 particles are believed to be the most harmful, as when inhaled they can penetrate deep into the lungs. The aim of this study was to examine the relationship between PM2.5 daily air concentrations and pediatric emergency department (ED) visits for respiratory diseases in a Greek suburban area. All pediatric ED visits for asthma-, pneumonia- and upper respiratory infection (URI)-related complaints were recorded during the one-year period. The 24-h PM2.5 air pollution data were prospectively collected from twelve fully automated air quality monitoring stations. The mean annual concentration of PM2.5 was 30.03 μg/m3 (World Health Organization (WHO) Air Quality Guidelines (AQG) Annual mean concentration: 10 μg/m3). PM2.5 levels rose above the WHO Air Quality Guidelines (AQG) 24-h concentrations (25 μg/m3)), 178 times (48.6% of the study period). When PM2.5 levels were above the daily limit, an increase of 32.44% (p < 0.001) was observed in daily pediatric ED visits for respiratory diseases and the increase was much higher during spring (21.19%, p = 0.018). A 32% (p < 0.001) increase was observed in URI-related visits, when PM2.5 levels were ≥25 μg/m3, compared to the mean daily visits when PM2.5 levels were <25 μg/m3. Air pollution levels were associated with increased pediatric ED visits for respiratory-related diseases.